SCHEMBL2097723

SCHEMBL2097723

[CH2]C(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.65
TSHR P16473 1/20 0.65
CASP1 P29466 1/20 0.65
ALDH1A1 P00352 4/20 0.59
MAPK1 P28482 1/20 0.59
HIF1A Q16665 1/20 0.59
MAPT P10636 3/20 0.57
KDM4E B2RXH2 1/20 0.57
ERCC5 P28715 1/20 0.52
FEN1 P39748 1/20 0.52
SRD5A2 P31213 1/20 0.52
POLB P06746 3/20 0.51
HPGD P15428 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.49
THRB P10828 1/20 0.49
RECQL P46063 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3038177 0.82 ALDH1A1 (0.65) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL30185351 0.81 SMN1; SMN2 (0.71) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL195020 0.81 SMN1; SMN2 (0.71) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL8065539 0.81 SMN1; SMN2 (0.71) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL180845 0.81 SMN1; SMN2 (0.71) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL5732135 0.79 SMN1; SMN2 (0.68) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL111279 0.79 TSHR (1.00) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL107060 0.79 SMN1; SMN2 (0.68) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL19998346 0.79 SMN1; SMN2 (0.68) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL11255876 0.78 FLT1 (0.50) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1243581-B1 Pyridinium compounds useful for the treatment of AGE-related diseases TORRENT PHARMACEUTICALS LTD (IN) 2005-07-13 EP claimed
EP-0019440-B1 BENZIMIDAZOLONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PFIZER INC. (US) 1982-09-29 EP claimed
EP-0019440-A1 Benzimidazolone derivatives, process for their preparation and pharmaceutical compositions containing them PFIZER INC. (US) 1980-11-26 EP claimed
US-4209527-A ANTIDIABETIC AGENTS PFIZER INC. (US) 1980-06-24 US claimed
US-4075340-A ANTIINFLAMMATORY, ANTIARRYTHMIC, ANTICOAGULANTS PARCOR (FR) 1978-02-21 US claimed
JP-58043954-A None JP disclosed
JP-58074669-A None JP disclosed
US-8785425-B2 11β-hydroxyandrosta-4-ene-3-ones SUN PHARMA ADVANCED RESEARCH COMPANY LTD. 2014-07-22 US disclosed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-20090054388-A1 NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES SUN PHARMA ADVANCE RESEARCH COMPANY (IN) 2009-02-26 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-0228876-A2 Esters of dihydrolysergic acid and related compounds ELI LILLY AND COMPANY (US) 1987-07-15 EP disclosed
JP-S5874669-A PREPARATION OF PYRAZOLE DERIVATIVE ISHIHARA SANGYO KAISHA LTD 1983-05-06 JP disclosed
JP-S5843954-A PYRAZOLE DERIVATIVE ISHIHARA SANGYO KAISHA LTD 1983-03-14 JP disclosed
EP-0019440-B1 BENZIMIDAZOLONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PFIZER INC. (US) 1982-09-29 EP disclosed
EP-0019440-A1 Benzimidazolone derivatives, process for their preparation and pharmaceutical compositions containing them PFIZER INC. (US) 1980-11-26 EP disclosed
US-4209527-A ANTIDIABETIC AGENTS PFIZER INC. (US) 1980-06-24 US disclosed
US-4000275-A BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES ELI LILLY AND COMPANY (US) 1976-12-28 US disclosed
US-3971825-A (5,6) (10,11) BIS-METHYLENE, BRONCHODILATORS SANKYO COMPANY LIMITED (JA) 1976-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 SMN1; SMN2 3787/4885TSHR 162/4885CASP1 1994/4885
US-20090054388-A1 NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES HSD11B1, HSD3B1, HSD3B2 SMN1; SMN2 4686/4885TSHR 801/4885CASP1 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.